NYSE: ARWR - Arrowhead Pharmaceuticals, Inc.

Rentabilité sur six mois: -27.56%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Arrowhead Pharmaceuticals, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. разрабатывает лекарства для лечения трудноизлечимых заболеваний в Соединенных Штатах.

plus de détails
В портфель компании входят ARO-AAT, терапевтический кандидат на РНК-интерференцию (РНКи), который проходит фазу II клинических испытаний для лечения заболеваний печени, связанных с дефицитом альфа-1-антитрипсина; ARO-APOC3, который проходит фазу I клинических испытаний для лечения гипертриглицеридемии; ARO-ANG3, который проходит фазу I клинических испытаний по снижению выработки ангиопоэтин-подобного белка 3; ARO-HSD для лечения заболеваний печени; ARO-ENaC для уменьшения продукции альфа-субъединицы эпителиального натриевого канала в дыхательных путях легких; и ARO-HIF2 для лечения светлоклеточного почечно-клеточного рака. Он также участвует в разработке JNJ-3989, подкожно вводимого терапевтического кандидата на РНКи третьего поколения для лечения хронической вирусной инфекции гепатита В; AMG 890 для снижения производства аполипопротеина А; и ARO-AMG1 для лечения нераскрытой генетически проверенной сердечно-сосудистой мишени. Arrowhead Pharmaceuticals, Inc. имеет лицензию и соглашение о сотрудничестве в области исследований с Janssen Pharmaceuticals, Inc. для разработки терапевтических препаратов с РНКи. Компания ранее была известна как Arrowhead Research Corporation и сменила название на Arrowhead Pharmaceuticals, Inc. в апреле 2016 года. Arrowhead Pharmaceuticals, Inc. была зарегистрирована в 1989 году, ее штаб-квартира находится в Пасадене, Калифорния.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 1993-06-16
ISIN US04280A1007
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт http://arrowheadpharma.com
Цена ао 18.49
Changement de prix par jour: -3.58% (21.53)
Changement de prix par semaine: +6.13% (19.56)
Changement de prix par mois: +5.76% (19.63)
Changement de prix sur 3 mois: +3.28% (20.1)
Changement de prix sur six mois: -27.56% (28.66)
Changement de prix par an: -37.88% (33.42)
Evolution du prix sur 3 ans: -59.27% (50.97)
Evolution du prix sur 5 ans: -20.15% (26)
Evolution des prix sur 10 ans: -0% (20.76)
Evolution des prix depuis le début de l'année: +5.76% (19.63)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 653.4 1
P/BV 12.14 1
P/E 478.56 1
EV/EBITDA -4.86 0
Total: 2.88

Efficacité

Nom Signification Grade
ROA, % -62.93 0
ROE, % -262.48 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.9092 10
Total: 9.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -95.96 0
Rentabilité Ebitda, % 543.94 10
Rentabilité EPS, % 496.16 10
Total: 8
Plus de détails

Date de transaction Date de divulgation Insider Taper Prix Volume Quantité Partagez jusqu'à, % Partager après, % Document
23.01.2025 27.01.2025 OLUKOTUN ADEOYE Y
Director		 Vente 21 20 139 959 0 0 lien
02.01.2025 06.01.2025 Anzalone Christopher Richard
Chief Executive Officer		 Vente 19.05 219 456 11520 0 -0.01 lien
27.12.2024 27.12.2024 OLUKOTUN ADEOYE Y
Director		 Achat 19.99 56 972 2850 0 0 lien
18.12.2024 20.12.2024 Anzalone Christopher Richard
Chief Executive Officer		 Vente 21.24 567 363 26712 0 -0.03 lien
17.12.2024 18.12.2024 GIVEN DOUGLAS B
Director		 Vente 22.04 12 056 547 0 0 lien
17.12.2024 18.12.2024 Waddill William D.
Director		 Vente 22.04 82 584 3747 0 0 lien
16.12.2024 18.12.2024 Vakiener Victoria
Director		 Vente 21.91 197 059 8994 0 -0.01 lien
16.12.2024 18.12.2024 GIVEN DOUGLAS B
Director		 Vente 21.9 109 500 5000 0 0 lien
16.12.2024 18.12.2024 Waddill William D.
Director		 Vente 21.9 82 081 3748 0 0 lien
20.03.2024 20.03.2024 Lu Hongbo
Director		 Achat 27.5 27 500 1000 0 0 lien
19.03.2024 20.03.2024 Lu Hongbo
Director		 Achat 28 28 000 1000 0 0 lien
18.03.2024 20.03.2024 Lu Hongbo
Director		 Achat 27.49 27 490 1000 0 0 lien
12.01.2024 17.01.2024 Hamilton James C
Chief Discovery/Trans Medicine		 Vente 36.89 292 907 7940 0 -0.01 lien
11.01.2024 16.01.2024 Vakiener Victoria
Director		 Vente 38.1 179 832 4720 0 0 lien
11.01.2024 16.01.2024 Ferrari Mauro
Director		 Vente 38.06 119 775 3147 0 0 lien
11.01.2024 16.01.2024 Waddill William D.
Director		 Vente 38.07 149 767 3934 0 0 lien
11.01.2024 16.01.2024 GIVEN DOUGLAS B
Director		 Vente 38.06 110 793 2911 0 0 lien
05.01.2024 05.01.2024 Hamilton James C
Chief Discovery/Trans Medicine		 Vente 35.18 1 130 790 32143 0 -0.03 lien
03.01.2024 05.01.2024 Hamilton James C
Chief Discovery/Trans Medicine		 Vente 32.19 202 797 6300 0 -0.01 lien
04.05.2023 05.05.2023 Anzalone Christopher Richard
Chief Executive Officer		 Vente 39.52 1 976 000 50000 0 -0.05 lien
04.05.2023 05.05.2023 Anzalone Christopher Richard
Chief Executive Officer		 Achat 2.01 100 500 50000 0 0.05 lien
03.05.2023 05.05.2023 Anzalone Christopher Richard
Chief Executive Officer		 Vente 39.14 2 149 880 54928 0 -0.05 lien
03.05.2023 05.05.2023 Anzalone Christopher Richard
Chief Executive Officer		 Achat 2.01 110 405 54928 0 0.05 lien
03.03.2023 06.03.2023 OLUKOTUN ADEOYE Y
Director		 Vente 32.65 370 578 11350 0 -0.01 lien
21.11.2022 22.11.2022 San Martin Javier
Chief Medical Officer		 Vente 29.99 584 805 19500 0 -0.02 lien
07.07.2022 11.07.2022 Anzalone Christopher Richard
Chief Executive Officer		 Achat 14.54 36 365 2501 0 0 lien
05.01.2022 07.01.2022 O'Brien Patrick
General Counsel		 Vente 61.72 2 005 900 32500 0 -0.03 lien
15.12.2021 17.12.2021 Anzalone Christopher Richard
Chief Executive Officer		 Vente 67.56 4 053 600 60000 0 -0.06 lien
12.01.2021 12.01.2021 Myszkowski Kenneth Allen
Chief Financial Officer		 Vente 81 116 721 1441 0 0 lien
11.01.2021 12.01.2021 Myszkowski Kenneth Allen
Chief Financial Officer		 Vente 81.02 939 589 11597 0 -0.01 lien
07.01.2021 08.01.2021 Hassard James
Chief Commercial Officer		 Vente 75 1 171 880 15625 0 -0.02 lien
06.01.2021 07.01.2021 Hamilton James C
Senior Vice President		 Vente 72.48 1 404 300 19375 0 -0.02 lien
06.01.2021 07.01.2021 Myszkowski Kenneth Allen
Chief Financial Officer		 Vente 72.44 2 218 480 30625 0 -0.03 lien
06.01.2021 07.01.2021 O'Brien Patrick
General Counsel		 Vente 72.41 1 810 250 25000 0 -0.03 lien
05.01.2021 07.01.2021 Hamilton James C
Senior Vice President		 Vente 72.53 1 405 270 19375 0 -0.02 lien
04.01.2021 05.01.2021 Waddill William D.
Director		 Vente 76.08 285 300 3750 0 0 lien
19.11.2020 20.11.2020 San Martin Javier
Chief Medical Officer		 Vente 69.39 1 353 100 19500 0 -0.02 lien

Établissements Volume Partager, %
Blackrock Inc. 13303757 10.74
Vanguard Group Inc 10672076 8.61
State Street Corporation 6825111 5.51
FMR, LLC 3371268 2.72
JP Morgan Chase & Company 2751048 2.22
Geode Capital Management, LLC 2326876 1.88
Invesco Ltd. 2306308 1.86
Credit Suisse Ag/ 1745342 1.41
Slate Path Capital, LP 1329000 1.07
Norges Bank Investment Management 1321927 1.07

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
Direxion mRNA ETF 3.66 0
Global X Genomics & Biotechnology ETF 3.13929 2.58 0.15585
ROBO Global Healthcare Technology and Innovation ETF 1.34674 19.56 0.37496
WisdomTree BioRevolution Fund 0.78711 -4.69 0.78691
FMC Excelsior Focus Equity ETF 0.72026 30.37 1.23
ProShares UltraShort Nasdaq Biotechnology 0.65 -40.36 1.76
Virtus LifeSci Biotech Clinical Trials ETF 0.62162 63.04 0.33
Invesco S&P MidCap 400® Pure Growth ETF 0.59742 23.48 1.51972
Syntax Stratified MidCap ETF 0.32279 17.66 1.56212
Direxion Daily S&P Biotech Bull 3x Shares 0.25658 4067.92 0.25924
Invesco Nasdaq Biotechnology ETF 0.2527 28.58 0.8565
Future Tech ETF 0.25063 426.34 0.8416
Principal Healthcare Innovators ETF 0.25063 618.5 0.8416
Amplify Etho Climate Leadership U.S. ETF 0.24703 22.79 1.41942
Pacer Lunt MidCap Multi-Factor Alternator ETF 0.22964 40.34 2.66358
Vanguard Russell 2000 Growth ETF 0.21 23.05 0.60264
Vanguard S&P Mid-Cap 400 Growth ETF 0.2 21.23 1.26071
iShares Russell 2000 Growth ETF 0.18363 38.04 0.6026
SPDR S&P 400 Mid Cap Growth ETF 0.17882 21 1.25693
ProShares Ultra Nasdaq Biotechnology 0.17149 51.7 0.85651
BNY Mellon US Small Cap Core Equity ETF 0.14423 30.07 1.75333
Vanguard Russell 2000 ETF 0.11 17.16 1.48801
SPDR S&P Midcap 400 ETF Trust 0.10469 19.52 1.64338
iShares ESG Screened S&P Mid-Cap ETF 0.10045 16.28 1.537
Vanguard S&P Mid-Cap 400 ETF 0.1 18.89 1.64344
JPMorgan Market Expansion Enhanced Equity ETF 0.09198 29.85 1.69513
Pacer Trendpilot US Mid Cap ETF 0.09133 19.31 1.64594
SPDR S&P Kensho New Economies Composite ETF 0.07999 21.57 0.88486
Direxion Daily Mid Cap Bull 3X Shares 0.07409 81.35 1.64688
ProShares Ultra MidCap400 0.07083 55.81 1.64562
Schwab U.S. Small-Cap ETF 0.06819 17.47 1.51433
JPMorgan BetaBuilders U.S. Mid Cap Equity ETF 0.06576 21.79 1.42082
iShares ESG Aware MSCI USA Small-Cap ETF 0.05442 18.09 1.49366
iShares Morningstar Small-Cap Growth ETF 0.0539 33.63 0.72598
iShares Morningstar Small-Cap Growth ETF 0.0539 587.89 0.72598
ProShares UltraPro Russell2000 0.05365 89.82 1.47873
iShares Morningstar Small-Cap ETF 0.05312 391.25 1.60498
iShares Morningstar Small-Cap ETF 0.05312 30.1 1.60498
iShares Morningstar Small Cap Value ETF 0.0519 26.7 2.50476
iShares Morningstar Small-Cap Value ETF 0.0519 201.65 2.50476
ProShares UltraPro MidCap400 0.04804 82.13 1.64397
Fidelity MSCI Health Care Index ETF 0.03451 3 1.46057
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.02443 31.36 1.41955
ProShares Hedge Replication ETF 0.01513 5.92 1.47892
Humankind US Stock ETF 0.01448 18.81 1.99919
Invesco FTSE RAFI US 1500 Small-Mid ETF 0.01408 17.58 1.75869
SPDR Portfolio MSCI Global Stock Market ETF 0.01026 17.99 2.19607
Vanguard ESG U.S. Stock ETF 0.01 23.54 1.26927
Vanguard Russell 3000 ETF 0.01 31.87 1.43817
Invesco S&P MidCap 400 Revenue ETF 0.00654 27.44 1.75091
iShares Dow Jones U.S. ETF 0.0049 25.05 1.41797
Schwab U.S. Broad Market ETF 0.00461 24.86 1.43354
iShares Russell 3000 ETF 0.00433 24.83 1.43482
SPDR Portfolio S&P 1500 Composite Stock Market ETF 0.00396 24.29 1.46083
Dimensional U.S. Core Equity 2 ETF 0.00308 30.76 1.47098
FlexShares Morningstar US Market Factor Tilt Index Fund 0.00259 21.94 1.69572
SPDR S&P 1500 Value Tilt ETF 0.00143 27.15 2.3833
SPDR S&P 1500 Momentum Tilt ETF 0.00021 38.25 1.12176
AGF U.S. Market Neutral Anti-Beta Fund -0.38512 -5.02 2.03993



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Kenneth A. Myszkowski Chief Financial Officer 834.34k 1966 (59 années)
Mr. Howard Lovy Director of Communications N/A
Dr. Mark M. Davis Ph.D. Founder and Founder & Director of Insert Therapeutics Inc & Calando N/A
Dr. Mark Seefeld Head of Toxicology & VP N/A 1954 (71 année)
Dr. Christopher R. Anzalone Ph.D. CEO, President & Director 1.6M 1969 (56 années)
Dr. James C. Hamilton M.D., MBA Chief of Discovery & Translational Medicine 762.14k 1978 (47 années)
Dr. Vincent Anzalone CFA Head of Investor Relations & VP N/A
Ms. Tracie Oliver Chief Commercial Officer 449.58k 1962 (63 année)
Dr. Bruce D. Given M.D. Chief Medical Scientist 486.31k 1954 (71 année)
Mr. Patrick O'Brien J.D., PharmD COO, General Counsel & Secretary 1964 (61 année)

Adresse: United States, Pasadena, CA , 177 East Colorado Boulevard - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: http://arrowheadpharma.com